Search results
Author(s):
Richard Pratley
Added:
10 months ago
EASD 24 - We are joined by Dr Richard Pratley (AdventHealth Diabetes Institute, US) to discuss the kidney, cardiovascular, metabolic, mortality and safety results from the FLOW trial.Interview Questions:1. What is the reasoning behind the FLOW Trial?2. What was the patient population and study design?3. What are the key results?4. Were there any surprising or unexpected findings?5. What further…
View more
Author(s):
Harriette Van Spall
,
Added:
7 months ago
AHA Conference 2024 — Semaglutide shows increased benefits in CKD patients based on their cardiovascular status and risk profile.Dr Harriette Van Spall (McMaster University, CA) sits down with Dr Katherine Tuttle (University of Washington, US) to discuss the effects of semaglutide in patients with chronic kidney disease (CKD).The FLOW trial (NCT03819153) is designed to assess the effect of…
View more
Author(s):
Vlado Perkovic
Added:
12 months ago
ADA 24 - In this succinct video, we are joined by Dr Vlado Perkovic (UNSW Sydney, Kensington, AU) to discuss a trial investigating the use of semaglutide in patients with type 2 diabetes and chronic kidney disease (NCT03819153).The FLOW trial enrolled 3533 participants with type 2 diabetes and chronic kidney disease, who were then randomized to recieve either semaglutide or placebo. The median…
View more
Author(s):
Firas Zahr
Added:
1 year ago
THT 24 - We are joined by Dr Firas Zahr (OHSU Knight Cardiovascular Institute Cardiology Clinic, US) to discuss the findings from the ALT FLOW Early Feasibility study (NCT03523416).The ALT FLOW Early Feasibility study aims to assess the initial clinical safety, functionality and effectiveness of a transcatheter atrial shunt system created by Edwards. 75 patients with symptomatic heart failure…
View more
Author(s):
Thomas Johnson
Added:
1 month ago
EuroPCR 25 - Substudy findings from ILUMIEN-IV show that virtual flow reserve was slightly higher after angiography guidance rather than an optical coherence tomography (OCT)-based physiology assessment after percutaneous coronary intervention (PCI) in high-risk angiographic lesions.We are joined by Dr Thomas Johnson (Bristol Heart Institute, Bristol, UK) to discuss findings from a retrospective…
View more
Author(s):
Jasper J Brugts
Added:
1 month ago
ESC HF 25 - TITRATE-HF shows 65% of patients with de novo heart failure receive guideline recommended medical therapy at 6 months in the Netherlands.Dr Jasper Brugts (Erasmus University Medical Centre, NL) joins us to discuss the outcomes from the TITRATE-HF study, which investigated adherence to the 2021 ESC guideline reccommendations for patients with heart failure with reduced ejecton fraction…
View more
Author(s):
Matthew J Budoff
Added:
3 months ago
ACC 2025 - Outcomes from colchicine in patients with stable coronary artery disease (CAD) shows significant plaque volume progression compared to placebo at one year.Dr Matthew Budoff (UCLA Medical Centre, Los Angeles, US) joins us onsite at ACC 2025 to discuss findings from the randomized, placebo-controlled, investigator-initiated EKSTROM trial (NCT06342609; Lundquist Institute for Biomedical…
View more
Rajiv Agarwal
Research Area(s) / Expertise:
Author
Author(s):
Johanna McChord
,
Astrid Hubert
,
Udo Sechtem
,
et al
Added:
8 months ago
Carolyn M Webb
Research Area(s) / Expertise:
Author